11:00 AM EDT, 06/25/2025 (MT Newswires) -- GSK (GSK) and Bharat Biotech International said Wednesday that they plan to progressively cut the price of the RTS,S malaria vaccine by more than half to less than $5 by 2028.

GSK and Bharat Biotech said they expect the phased price reduction to start immediately and be completed in 2028

The malaria vaccine was developed by GSK, PATH, and other partners, according to the companies, which said they expect RTS,S to be rolled out to 12 endemic countries in Africa by the end of 2025.

The companies pledged the price cut to Gavi, the Vaccine Alliance, and said they plan to realize the price reduction through process improvements, higher capacity, cost-effective manufacturing, and minimal profit margins.

Price: 38.39, Change: -0.29, Percent Change: -0.75